Agios Pharmaceuticals has presented detailed Phase 3 RISE UP trial results for mitapivat in sickle cell disease, strengthening the clinical case for an oral pyruvate kinase activator that targets red blood cell metabolism rather than only downstream complications of the disease. The 52-week data showed a statistically significant hemoglobin response compared with placebo, along with new analyses suggesting reduced transfusion burden and clinically meaningful benefits among patients who achieved hemoglobin response. The results were presented at the 31st European Hematology Association Congress, placing mitapivat in a sharper spotlight as Agios Pharmaceuticals pursues regulatory review in sickle cell disease.
The update matters because sickle cell disease remains a devastating inherited blood disorder despite advances in supportive care, disease-modifying therapy, and curative approaches for selected patients. Many patients continue to face chronic hemolytic anemia, vaso-occlusive pain crises, organ damage, fatigue, transfusion needs, and reduced quality of life. Mitapivat’s clinical profile is important because it is designed to improve red blood cell health by activating pyruvate kinase, potentially addressing hemolysis and anemia through a mechanism that is distinct from anti-sickling, anti-adhesion, anti-inflammatory, and gene-based strategies.
Why hemoglobin response remains central to mitapivat’s sickle cell disease case
The RISE UP trial’s strongest signal comes from hemoglobin response. Agios Pharmaceuticals previously reported that 40.6% of patients treated with mitapivat achieved the primary endpoint of hemoglobin response, defined as at least a 1.0 g/dL increase from baseline in average hemoglobin from Week 24 through Week 52, compared with 2.9% of patients receiving placebo. That difference is clinically relevant because chronic anemia is one of the defining features of sickle cell disease and can contribute to fatigue, reduced exercise capacity, organ stress, and long-term complications.
Mitapivat is designed to activate pyruvate kinase, an enzyme involved in red blood cell energy production. In sickle cell disease, red blood cells are under metabolic and structural stress. By increasing adenosine triphosphate and reducing 2,3-diphosphoglycerate, mitapivat may improve red blood cell function and reduce the tendency toward sickling and hemolysis. This mechanism gives the therapy a differentiated place in the treatment landscape because it focuses on red cell metabolism rather than directly editing genes or suppressing a single inflammatory pathway.
The hemoglobin response data are also important because they may help support the accelerated approval strategy. Agios Pharmaceuticals has submitted a supplemental New Drug Application to the United States Food and Drug Administration for mitapivat in sickle cell disease. In that context, regulators will evaluate whether the hemoglobin benefit is robust, durable, and clinically meaningful enough to support the proposed indication. The company’s new EHA 2026 analyses are aimed at strengthening that argument by showing that hemoglobin response may be associated with broader patient benefits.
How transfusion burden data could strengthen the clinical relevance of RISE UP
The new transfusion burden analysis gives the mitapivat story more clinical depth. Agios Pharmaceuticals reported that patients in the mitapivat arm had a 41.1% relative reduction in the proportion of patients requiring blood transfusions compared with placebo. The company also reported a 55.9% relative reduction in the average number of red blood cell units transfused per patient.
This matters because transfusion burden is not a minor supportive-care issue in sickle cell disease. Blood transfusions can be necessary and lifesaving, but repeated transfusions may create logistical, clinical, and immunologic challenges, including alloimmunization, iron overload, access concerns, and repeated healthcare utilization. A therapy that reduces transfusion need could therefore carry practical value for patients and physicians, even if it is not framed as the primary efficacy measure.
The transfusion findings also help address a broader question: whether improved hemoglobin response translates into clinical utility. Regulators and hematologists do not only want laboratory improvements. They want evidence that a therapy changes the lived disease burden. Reduced transfusion dependence may support the idea that mitapivat’s anti-hemolytic activity has consequences beyond a numeric hemoglobin increase.
Still, the transfusion data should be interpreted carefully. The analysis adds support, but it does not erase the fact that the trial’s sickle cell pain crisis endpoint was not statistically significant across the overall study population. The clinical story for mitapivat is therefore not a simple across-the-board success narrative. It is more nuanced: strong hemoglobin response, supportive hemolysis and transfusion signals, and selected patient-reported and healthcare-utilization benefits among responders, balanced against a missed pain-crisis endpoint.
Why the pain-crisis result keeps the mitapivat debate clinically nuanced
The RISE UP trial included two primary endpoints: hemoglobin response and annualized rate of sickle cell pain crises. Mitapivat met the hemoglobin response endpoint, but the annualized pain-crisis endpoint did not reach statistical significance in the overall population. That distinction is central to how clinicians will interpret the program.
Pain crises are among the most visible and disruptive complications of sickle cell disease. They drive emergency room visits, hospitalizations, opioid exposure, missed school and work, and major quality-of-life disruption. A therapy that significantly reduces crises across a broad population would have an especially strong clinical argument. Because mitapivat did not meet that endpoint overall, the therapy’s potential role may be more closely tied to anemia, hemolysis, transfusion burden, and benefits in patients who achieve hemoglobin response.
Agios Pharmaceuticals reported that patients in the mitapivat arm who achieved hemoglobin response had clinically meaningful reductions in sickle cell pain crises and related hospitalizations compared with non-responders. The company also reported improvements in fatigue, pain, sleep, physical function, and healthcare utilization among hemoglobin responders. These findings suggest that a responder-defined benefit may exist, but post-hoc and subgroup analyses require cautious interpretation.
This is likely where the regulatory and clinical debate will sharpen. If hemoglobin response identifies patients most likely to experience broader clinical improvement, physicians may eventually consider mitapivat as a therapy for patients with significant anemia or hemolysis-driven disease burden. However, the absence of a statistically significant overall pain-crisis endpoint may limit how strongly the drug can be positioned around crisis prevention unless regulators or future studies support that claim.
What safety data suggest about mitapivat’s potential long-term use
Safety remains a key part of mitapivat’s clinical profile because sickle cell disease is chronic and patients may require long-term therapy. Agios Pharmaceuticals said mitapivat was well tolerated in RISE UP, with a safety profile consistent with previous sickle cell disease trials. The company reported that treatment-emergent adverse events occurred at similar rates between the mitapivat and placebo arms, and no treatment-related deaths occurred during the trial.
That safety profile is important because any oral chronic therapy in sickle cell disease must be acceptable for sustained use across a diverse patient population. Patients may already be taking hydroxyurea, managing organ complications, and receiving episodic acute care. A therapy that adds meaningful benefit but creates substantial tolerability concerns may face adoption barriers.
Mitapivat’s oral administration could be a practical advantage if approved. Oral therapies can be easier to integrate into routine care than infusion-based regimens or complex procedures, although adherence remains important. In sickle cell disease, daily medication burden is already a concern, so physicians will need to weigh convenience, efficacy, safety, patient motivation, and access.
The safety discussion will also be influenced by existing experience with mitapivat in other hemolytic anemias. Agios Pharmaceuticals has emphasized broader clinical exposure across its mitapivat development program. That background may help clinician familiarity, but the sickle cell disease population has distinct risks, comorbidities, and treatment needs, so disease-specific evidence remains essential.
How mitapivat could fit into a changing sickle cell disease treatment landscape
The sickle cell disease treatment landscape is evolving quickly. Hydroxyurea remains foundational for many patients, while transfusion strategies, supportive care, recently developed medicines, and curative approaches such as stem cell transplantation and gene therapies all shape treatment decisions. However, access, eligibility, cost, infrastructure, long-term safety, and patient preference continue to limit the reach of more complex interventions.
Mitapivat could fit into this landscape as an oral disease-modifying therapy focused on improving red blood cell health and reducing hemolytic burden. That may make it relevant for patients who have persistent anemia, transfusion needs, or hemolysis-related complications, including those who are not candidates for curative therapy or who prefer a less intensive treatment option.
The key question is how broad the potential label and clinical use case would be. If regulators view hemoglobin response and supporting analyses as sufficient, mitapivat could become a new option for a defined sickle cell disease population. If the FDA focuses heavily on the missed pain-crisis endpoint, the review may become more complicated. The final regulatory outcome will determine whether mitapivat enters practice as a broad sickle cell therapy, a more targeted anemia-focused option, or a drug requiring additional evidence.
For clinicians, the most useful future data may involve identifying which patients are most likely to respond. Biomarkers, baseline hemoglobin, hemolysis markers, hydroxyurea use, genotype, transfusion history, and prior crisis burden could all influence how mitapivat is used if approved. The more clearly physicians can identify likely responders, the stronger the therapy’s real-world role may become.
Why RISE UP could still be important despite a mixed endpoint profile
The RISE UP data present a clinically meaningful but not uncomplicated picture. Mitapivat clearly demonstrated a strong hemoglobin response, and the new analyses add encouraging evidence around transfusion burden and outcomes in hemoglobin responders. At the same time, the missed overall sickle cell pain-crisis endpoint prevents the data from being a clean, unqualified win across every major clinical dimension.
That nuance does not make the program weak. It makes the review more interesting. Sickle cell disease is heterogeneous, and not every clinically useful therapy needs to solve every aspect of the disease. A treatment that improves anemia, reduces hemolysis, lowers transfusion burden, and benefits a responder population could still have meaningful value, especially if safety and oral administration support long-term use.
The next major test will be how regulators evaluate the complete sNDA package and how hematologists interpret the RISE UP results in the context of current treatment options. If approved, mitapivat could add a new oral mechanism to sickle cell disease care. If questions remain around clinical endpoints or patient selection, Agios Pharmaceuticals may need additional evidence to define the therapy’s role more clearly.
For now, the RISE UP results move mitapivat into a more serious clinical conversation. The therapy may not be a universal answer for sickle cell disease, but it could become an important option if its anti-hemolytic profile translates into durable patient benefit for the right population.
